Starten Sie Ihre Suche...

Durch die Nutzung unserer Webseite erklären Sie sich damit einverstanden, dass wir Cookies verwenden. Weitere Informationen

A phase II, randomized, double-blind, placebo-controlled study comparing the combination of CNTO 328 (anti-IL-6 monoclonal antibody) and Velcade versus Velcade alone in subjects with relapsed or refractory multiple myeloma

Laufzeit: 01.01.2008 - 31.12.2011


Subjects with a confirmed diagnosis of multiple myeloma and measurable secretory disease. Additionally, subjects must have documented disease progression during or after an initial response to at least 1 but no more than 3 prior lines of therapy or have no response to previous treatment (primary refractory disease). Subjects previously treated with bortezomib, and subjects who failed prior therapy
with high-dose dexamethasone will be excluded.

Beteiligte Einrichtungen